KRAS Inhibitor Daraxonrasib Shows Promise in Pancreatic Cancer
Revolution Medicines' daraxonrasib shows meaningful responses in KRAS-mutant pancreatic cancer in Phase 2 data, marking a breakthrough in a notoriously hard-to-treat disease.
Oncology
The latest oncology coverage from Hawaii Medical Journal.
Revolution Medicines Raises $2B After Pancreatic Cancer Trial
Revolution Medicines closed a $2 billion raise after Phase 3 data showed daraxonrasib doubled median overall survival in advanced pancreatic cancer.
Pancreatic Cancer Pill Doubles Survival in New Trial
Revolution Medicines' daraxonrasib nearly doubled median survival in metastatic pancreatic cancer patients compared to chemotherapy, according to new data.
Merck Acquires Terns Pharmaceuticals for $6.7B in 2026
Merck's $6.7B acquisition of Terns Pharmaceuticals targets TERN-701, a leukemia drug that could shore up its oncology pipeline amid patent pressures.
By James Liu